Company Overview of Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products comprising EDP-788 for the treatment of methicillin-resistant Staphylococcus aureus ba...
500 Arsenal Street
Watertown, MA 02472
Founded in 1995
Key Executives for Enanta Pharmaceuticals, Inc.
Chief Executive Officer
Total Annual Compensation: $683.9K
Chief Financial Officer
Total Annual Compensation: $420.2K
Chief Scientific Officer and Senior Vice President of Research & Development
Total Annual Compensation: $486.4K
Compensation as of Fiscal Year 2013.
Enanta Pharmaceuticals, Inc. Key Developments
Enanta Pharmaceuticals, Inc. Announces U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Regimen for Genotype 1 Chronic Hepatitis C
Jun 13 14
Enanta Pharmaceuticals, Inc. announced that the New Drug Application for AbbVie's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. The three direct-acting antiviral investigational regimen consists of the fixed-dose combination of ABT-450/ritonavir (150/100mg) co-formulated with ombitasvir (ABT-267) 25mg, dosed once daily, and dasabuvir (ABT-333) 250mg with or without ribavirin (weight-based), dosed twice daily. ABT-450 is Enanta's lead protease inhibitor developed through Enanta's collaboration with AbbVie. The NDA was submitted on April 21, 2014 and is supported by data from a large clinical program being conducted by AbbVie, including six phase 3 studies of more than 2,300 GT1 patients in over 25 countries. The regimen was granted a Breakthrough Therapy designation by the FDA in May 2013, a status given to investigational treatments for serious or life-threatening conditions with preliminary clinical evidence demonstrating substantial improvement on at least one clinically significant endpoint compared to available therapy. In May 2014, AbbVie submitted marketing authorization applications (MAAs) for regulatory approval in the European Union.
Enanta Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 02:00 PM
Jun 2 14
Enanta Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 02:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Jay R. Luly, Chief Executive Officer, President and Director.
Enanta Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2014
May 12 14
Enanta Pharmaceuticals, Inc. announced consolidated earnings results for the second quarter and six months ended March 31, 2014. For the quarter, the company announced revenue of $2,160,000 compared to $1,196,000 for the same period a year ago. Loss from operations was $5,127,000 compared to $4,001,000 for the same period a year ago. Net loss was $5,203,000 compared to $3,749,000 for the same period a year ago. Net loss attributable to common stockholders was $5,203,000 or $0.28 per diluted share compared to $4,993,000 or $2.28 per diluted share for the same period a year ago. The changes in revenue for the three and six-month periods were primarily related to the timing and amount of milestone and other payments from collaborations, which have varied significantly from period to period and are expected to continue to do so.
For the six months, the company announced revenue of $3,053,000 compared to $29,055,000 for the same period a year ago. Loss from operations was $10,584,000 compared to income from operations of $17,908,000 for the same period a year ago. Net loss was $10,573,000 compared to net income of $18,208,000 for the same period a year ago. Net loss attributable to common stockholders was $10,573,000 or $0.58 per diluted share compared to net income attributable to common stockholders of $2,012,000 or $1.09 per diluted share for the same period a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|